http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories
-
Merck and Moderna Will Present Results From Landmark Phase 3 INTerpath-001 Trial for Intismeran Autogene Plus KEYTRUDA® (pembrolizumab) at ESMO 2026 Presidential Symposium
-
EU approves Merck's Keytruda plus Padcev for bladder cancer
-
European Commission Approves KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as Perioperative Treatment for Adults With Resectable Muscle-Invasive Bladder Cancer (MIBC)
-
Merck to present Phase 3 oncology data at ESMO 2026 congress
-
Merck Showcases First-Time Pivotal Phase 3 Results From Oncology Pipeline and Continued Innovative Potential of Existing Portfolio at ESMO 2026
-
Merck eye drug matches anti-VEGF in DME trial with safety caveats
-
Merck Presents One-Year Results from the Pivotal Phase 2b/3 BRUNELLO Study Evaluating Remigromig, a Tri-specific Agonist of the Wingless-related Integration Site (Wnt) Pathway, in Adults with Diabetic
-
Merck to Hold Third-Quarter 2026 Sales and Earnings Conference Call Oct. 29
-
Merck's tulisokibart meets goals in skin disease Phase 2b trial
-
Merck's Tulisokibart Met Primary and Key Secondary Endpoints in Phase 2b Study in Patients With Moderate to Severe Hidradenitis Suppurativa (HS)
-
Merck licenses oral cancer drug candidate for up to $2.13 billion
-
Merck Enters into Exclusive Global License Agreement with SciBrunch Therapeutics for SPR2015, an Investigational Oral KRAS G12D (ON) Inhibitor
-
Merck and Daiichi Sankyo withdraw lung cancer drug application
-
Ifinatamab Deruxtecan Biologics License Application for Certain Patients with Previously Treated Extensive-Stage Small Cell Lung Cancer Voluntarily Withdrawn
-
FDA approves Merck and Eisai kidney cancer combination therapy
-
U.S. FDA Approves WELIREG® (belzutifan) Plus LENVIMA® (lenvatinib) for Certain Previously Treated Adult Patients With Advanced Renal Cell Carcinoma With a Clear Cell Component (ccRCC)
-
Merck's remigromig meets primary endpoint in DME phase 2b/3 trial
-
Merck’s Remigromig, a Tri-specific Agonist of the Wingless-related Integration Site (Wnt) Pathway, Met Primary Endpoint in the Pivotal Phase 2b/3 BRUNELLO Study of Adults with Diabetic Macular Edema
-
FDA updates Merck's Winrevair label with early PAH trial data
-
U.S. FDA Approves Update to the Label for WINREVAIR™ (sotatercept-csrk) to Include Data from the Phase 3 HYPERION Trial Evaluating Adults Recently Diagnosed with Pulmonary Arterial Hypertension (PAH
-
Japan approves Merck's subcutaneous pembrolizumab for all Keytruda uses
-
Merck’s KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph) Approved in Japan for Subcutaneous Administration for All KEYTRUDA® (pembrolizumab) Indications Approved in Japan
-
EU panel backs Merck's Keytruda plus Padcev for bladder cancer
-
Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as Perioperative Treatment for Adults With Resectable Muscle-Invasive Bladder Cancer (MIB
-
Merck Launches Your Hive of Whole Health to Support Whole Person Care for People Living With HIV
-
Merck to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
-
Merck to Participate in the Wells Fargo 21st Annual Healthcare Conference
-
Merck and Moderna's melanoma drug combo beats Keytruda alone in trial
-
Merck and Moderna Announce Phase 3 INTerpath-001 Trial of Intismeran Autogene Plus KEYTRUDA® Met Endpoints of Recurrence-Free Survival (RFS) and Distant Metastasis-Free Survival (DMFS) in Patients Wi
-
FDA accepts Merck's sBLA for Enflonsia to cover second RSV season
-
U.S. FDA Accepts sBLA for ENFLONSIA™ (clesrovimab-cfor) to Update its Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease Indication to Include Children Under Two Years at Increased Ri
-
Merck Announces Fourth-Quarter 2026 Dividend
-
Merck signs HIV prevention drug licenses covering 129 countries
-
Merck Announces Initial Access Plans for Alimatravir, an Investigational Once-Monthly Oral HIV Pre-Exposure Prophylaxis in Phase 3 Development
-
Gilead and Merck HIV pill shows strong results in Phase 3 trials
-
Investigational Once-Weekly Oral HIV Treatment Regimen of Islatravir and Lenacapavir Maintained Virological Suppression in Adults With HIV Who Switched Antiretroviral Therapy
-
MilliporeSigma Announces Opening of BioReliance® Testing Facility in Darmstadt, Germany to Support Drug Product Release in Europe
-
FDA approves Merck's Lipfendra as first oral PCSK9 inhibitor
-
Merck’s LIPFENDRA® (enlicitide) is the First and Only Once-Daily Oral PCSK9 Inhibitor Approved by the U.S. FDA to Reduce LDL-C in Adults with Hypercholesterolemia
-
Merck to present HIV pipeline data at AIDS 2026 conference
-
Merck to Present New Data on Daily, Weekly, and Monthly Options Across its HIV Treatment and Prevention Pipeline at AIDS 2026
-
Merck's Keytruda meets PFS endpoint in endometrial cancer trial
-
KEYTRUDA® (pembrolizumab) as Monotherapy Significantly Improved Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer With Mismatch Repair Deficient (dMMR)
-
FDA clears Merck's Keytruda combo for muscle-invasive bladder cancer
-
FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each With Padcev® (enfortumab vedotin-ejfv), as Treatment Before and After Surgery for Ad
-
Merck to Hold Second-Quarter 2026 Sales and Earnings Conference Call Aug. 4
-
Merck reaches deal to expand HIV drug access via ADAP programs
-
Merck Announces New Agreement with ADAP Crisis Task Force to Improve Access and Care for People Living with HIV
-
FDA approves Merck's Keytruda combo with Trodelvy for TNBC
-
FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), each with Trodelvy® (sacituzumab govitecan-hziy) as First-Line Treatment of PD-L1+ (CPS �
